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Abstract 
The aim of the study was to investigate for the first time the preparation, physical properties and macrophage activating effect of 
sterically stabilized liposomes made from hexadecylphosphocholine (HPC, Miltefosine ®) using different poly(ethylene glycol) lipids for 
coating. We could demonstrate hat it is possible to prepare different liposomal vesicle types (MLV, SUV and LUVET) without any 
problem and with a high stability in buffer (release of hydrophilic marker was < 5% after half a year) and in plasma (t~/2 up to several 
days). The preparation method, including size of polycarbon membrane filter used for the preparation of LUVETs had the main influence 
on vesicle size and size distribution. The addition of a charged lipid like DCP and different amounts of PEG-lipid up to 10% had no effect 
on size and stability of PEG-LUVETs. A comparison of activating potency of PEG-HPC-vesicles with commonly used HPC-liposomes 
was performed with mouse peritoneal macrophages. HPC-liposomes induced a clear release of NO and TNF from mouse peritoneal 
macrophages pecially in a synergistical action with LPS. On the contrary the effect of PEG-liposomes was similar to control cells after 
a combined activation in vivo/in vitro. The reduced interaction of these liposornes with the MPS was also demonstrated byan unchanged 
carbon ink uptake after treatment of mice (i.p.) with liposomes prepared with and without PEG-lipid. PEG-HPC-liposomes combine the 
advantages of HPC, liposomes and PEG-coating, resulting in a promising preparation for treatment of mammary cancers. 
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1. Introduction 
Hexadecylphosphocholine (HPC, Miltefosine ~) is the 
main representative of a new generation of synthetic lipids 
with a very simple structure. Although HPC has a very 
simple structure it has been found to have a strong antineo- 
Abbreviations: APC, alkylphosphocholine; CF, 6(5)-carboxyfluo- 
rescein; CH, cholesterol; DCP, dicetyl phosphate; DPPE, dipalmitoylglyc- 
erophosphoethanolamine; DSPE, distearylglycerophosphoethanolamine; 
EPC, eicosanylphosphocholine; FCS, heat inactivated fetal calf serum; 
HEPC, hydrated egg yolk phosphocholine; HPC, hexadecylphospho- 
choline; LPS, lipopolysaccharide; LUVET, large unilamellar vesicle by 
extrusion technique; MLV, multilamellar vesicle; MPS, monocyte phago- 
cytic system; NO, nitroxide; PBS, phosphate-buffered saline solution; 
PEG, poly(ethylene glycol); PI, polydispersity index; PT, plateau time; 
SUV, small unilamellar vesicle; TPC, tetradecylphosphocholine; TNF, 
tumor necrosis factor. 
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plastic activity in rats bearing MNU-induced, au- 
tochthonous mammary carcinomas [1,2]. Recently we could 
demonstrate that HPC is additional therapeutically active 
after i,v. or i.p. application in different human mammary 
carcinomas xenotransplanted to nude mice [3,4]. 
Beside the superior effect of topical treatment of skin 
metastasis originated from mammary carcinomas [5] the 
therapeutic effect following systemic application in human 
carcinomas was disappointing [6,7]. Because HPC and 
related alkylphosphocholines are able to form stable lipo- 
somes by themselves if cholesterol and a charged compo- 
nent like dicetyl phosphate is added [3], it should be 
possible to improve the therapeutic index of APC by using 
it in liposomal form. 
A disadvantage for the in vivo use of liposomal prepara- 
tions is their preferred elimination from circulation by the 
mononuclear phagocytic system (MPS) [8]. On the basis of 
several experimental data it is possible to control this 
uptake by the variation of liposome composition [9-15]. 
The influence of size [10,11], variation of liposomal con- 
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stituents like cholesterol [ 12,13], surface charge [14], addi- 
tion of phosphatidylserine [11] or gangliosides [14] are 
possibilities to influence the uptake of liposomes. Best 
results have been obtained by the incorporation of phos- 
phoethanolamine derivatives of poly(ethylene glycol) 
which result in sterically stabilized liposomes (PEG- or 
Stealth ~'liposomes) with an enhanced time of circulation 
in vasculature ([15-18], for review see [8]). Subsequently 
an increase in drug targeted by liposomes was found in 
tumor tissue [19,20]. 
Based on our experience with multilamellar (MLV) and 
small unilamellar vesicles (SUV) made from HPC or other 
alkylphosphocholines [3,4,21-24] our intention was now 
to investigate for the first time the preparation and proper- 
ties of sterically stabilized HPC-liposomes. Stability and 
interaction with the phagocytic system in vitro and in vivo 
were of special interest, as these properties are important 
preconditions for a successful therapeutic use of these new 
liposomal preparations. 
2. Materials and methods 
N-(M ethoxypolyethyleneglycol)- 1,2-distearoyl-sn- 
glycero-3-phosphoethanolamine, Na salt (PEG20o0DSPE) 
and N-(methoxypolyethyleneglycol)-l,2-dipalmitoyl-sn- 
glycero-3-phosphoethanolamine, Na salt (PEGe000DPPE), 
each with about 45 repetitive ethoxy-units and 
PEGs000DPPE with about 110 repetitive units were pur- 
chased from Sygena (Liestal, Switzerland). HPC was a gift 
from Dr. Hilgard (ASTA Medica, Frankfurt, Germany) and 
was stored in a desiccator at room temperature. Hydrated 
egg-yolk lecithin (HePC, Phospholipon 100H) was ob- 
tained from Nattermann Phospholipid (K~51n, Germany). 
Dicetyl phosphate (DCP), cholesterol (CH) and calcein 
were purchased from Serva (Heidelberg, Germany). CH 
was recrystallized from acetone prior to use. 5(6)-Carbo- 
xyfluorescein (Eastman Kodak Company, Rochester, NY, 
USA) was purified on Sephadex LH20 [25]. 
Methyl[3H]thymidine was obtained from Amersham Buch- 
let (Braunschweig, Germany). Sulfanilamide, H3PO 4, 
NaNO 2 and lipopolysaccharide from Escherichia coli, 
serotype 055:B5 were purchased from Fluka (Buchs, 
Switzerland), N-(1-naphthyl)ethylenediamine dihydrochlo- 
ride from Sigma-Aldrich (Deisenhofen, Germany); aque- 
ous glutardialdehyde (25%), stabilised with Amberlyst A21 
and Triton X-100 from Ferak (Berlin, Germany). 
2. I. Preparation and characterisation of  liposomes 
Vesicles were prepared from APC or HePC, CH and 
DCP in a molar ratio of l: 1:0.2 (l ipid/CH/DCP) by the 
lipid layer method. For the preparation of PEG-liposomes 
additional PEG-lipid (5-10 mol%) was added as indicated 
in tables and figures. The lipid film was hydrated with 
phosphate-buffered saline solution (PBS, pH 7.4) for MLV 
preparation and small unilamellar vesicles (SUV) were 
prepared by repeated sonication from these MLV as re- 
ported [3]. 
SUV or large unilamellar vesicles (LUVET) for deter- 
mination of stability were obtained from the respective 
MLV, prepared by hydration of the lipid film with 150 
mM CF (PBS) or 50 mM calcein (water). The total amount 
of encapsulated fluorescence marker was determined mea- 
suring the fluorescence intensity using the spectrofluorom- 
eter MK 1 (FARRAD Optical, New York, USA) at excita- 
tion wavelength of 490 nm and an emission wavelength of 
520 rim. Liposomes were destroyed by addition of Triton 
X-100 (final concentration 2%) and concentrations were 
calculated from standard curves. 
LUVET were prepared by the extrusion technique ac- 
cording to MacDonald et al. [26]. MLV-suspensions (1 
mM or 20 raM) was passed repeatedly (usually 19 times) 
through polycarbon membranes of defined pore size using 
a LiposoFast tr" Basic system (Avestin, Ottawa, Canada). 
Liposomes (SUV and LUVET) were separated from 
free fluorescence marker after preparation by gel chro- 
matography on Sephadex G-75, MLV were washed repeat- 
edly by centrifugation (20000× g) and resuspended in
PBS. 
The lipid content and liposomal composition of the 
preparations were determined by high-performance thin- 
layer chromatography (Automated Multiple Development 
System and Linomat IV; CAMAG, Muttenz, Switzerland). 
Vesicle size determination was performed by dynamic 
light scattering measurement a an angle of 90 with a 
Coulter Counter N4 MD model and the AccuComp ~ Sys- 
tem (Coulter Electronics, Hialeah, USA). Mean particle 
size was calculated by SDP analysis. Size distribution 
(based on solid sphere weight results) is given as polydis- 
persity index (PI) - varying from 0 (entirely mono- 
disperse) to 1 (completely polydisperse suspension). 
2.2. Characterization of  liposomal stabilit 3" 
For the characterization f stability in buffer the deter- 
mination of CF leakage from liposomes was performed by 
using fluorescence measurements a described previously 
[21]. Liposomes were stored at 4°C and the release was 
monitored at least for 6 months. 
As a marker for vesicular stability of HPC-liposomes in 
plasma the release of the fluorescence marker calcein was 
determined according to Allen and Cleland [27]: Suspen- 
sions of MLV, SUV and LUVETs with encapsulated cal- 
cein were prepared as described above and finally diluted 
to a concentration f 2 mM with PBS. Immediately before 
measurement 50 I~1 of these suspensions were added to 
950 txl of human plasma. This corresponds with concentra- 
tions of HPC used for experiments in vivo [4,28] 
The fluorescence intensity at t = 0 minutes of each 
sample was defined as ~tart" The increase in intensity was 
then followed at 25°C for at least 24 h. For determination 
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of the total amount of encapsulated marker (Ffina 1) finally 
Triton X-100 was added to the plasma until non increase 
in fluorescence was observed (25-150 ~1). 
Stability of liposomes was compared based on time 
necessary to reach a plateau level with minimum of change. 
This plateau time (PT) is given as the mean time point of 
the first time period over 30 min with a change in fluores- 
cence ~F  < 1%/10 rain. 
If possible, T~/2 is given for the time for release of 50% 
of marker and was calculated as follows: 
F(T , /2 )  = (1/2) (F f i ,~ l -  F,,~rt) -~ Fstarl 
T~/2 was then determined from the plot of the release 
curve at F(T1/2). 
All determinations were done at least twice. 
2.3. Influence on peritoneal macrophages 
Actication. Mouse macrophages were derived from the 
peritoneum of Balb/c mice 4 days after a single i.p. 
injection of 0.2 ml PBS with 80 I.tmol/1 HPC-MLV or 
PEG-HPC-MLV by peritoneal lavage. Control 
macrophages were harvested without any in vivo pretreat- 
merit. The viability of macrophages was controlled by 
trypan blue exclusion and was always > 95%. All cells 
were cultured in RPMI-1640 medium (Gibco) and supple- 
mented with 2 btmol/ml t-glutamine (Flow Labs), peni- 
cillin G (100 units/ml), streptomycin (100 l ig/ml,  both 
from Gist-Brocades) and heat-inactivated fetal calf serum, 
(10% FCS, Gibco). All the reagents except LPS were free 
of endotoxin contaminations a determined by the Limulus 
amoebocyte lysate assay (purchased from Bio * Whittaker, 
Walkersville, USA; sensitivity < 0.1 ng/ml). 
Test- or control macrophages (1 - 105 in 200 t*1 RPM! 
1640/well) were incubated in a 96-well-microtiter plate 
(Costar) in the absence (control) or presence of MLV (100 
IxM) or LPS (50 txg/ml) for 4 h or 48 h at 37°C in a 
humidified atmosphere containing 5% CO 2. 
TNF assay. Macrophages from mice treated with lipo- 
somes before or from untreated mice were cocultered with 
the indicated reagents for 4 h. Culture supernatants were 
assayed for TNF activity using the L 929 bioassay [29] and 
human recombinant TNF (Biozol) for standard as de- 
scribed previously [23]. 
The mean of TNF-release factor (TR) is given, calcu- 
lated from TNF, released after treatment with the indicated 
agents, divided by the TNF released from control (un- 
treated) macrophages. The mean TNF-release of control 
macrophages was 41.3 _+ 28.3 pg/ml.  
NO assay. NO secretion from macrophages was deter- 
mined in supernatants after 4 and 48 h of incubation with 
100 mmol/1 MLV by measuring the total concentration of
NO 2, a stable reaction product of NO, according to Ding 
et al. [30] as reported [21]. 
The absorbance was measured with a Spectra II Pho- 
tometer (SLT) at 560 nm. The concentration of NO was 
calculated from a sodium nitrite standard curve and given 
in ng/ml. All determinations were carried out in duplicate 
in at least three independent experiments. 
Carbon clearance in vivo. This experiment was used 
for measurement of the interaction of liposomes with the 
MPS as described earlier [31]. Briefly, four mice per group 
received equimolar doses of free HPC, HPC-SUV, PEG- 
HPC-SUV or physiological saline (for control). India ink 
was administered i.v. at certain times (for details see Fig. 
5). Remaining ink was determined spectroscopically at 650 
nm in 25 ixl blood samples, taken from the retroorbital 
venus plexus. The elimination half life is given for India 
ink (tl/2). 
3. Results 
3. I. Preparation and properties of LUVETS 
SUV prepared by conventional sonification (Table 1) 
show a size of 74_+ 28 nm (PI: 0.31), the diameter for 
PEG-SUV were found to be e.g. for PEG2000DSPE 86 + 26 
nm (PI: 0.14). 
Large unilamellar vesicles were prepared from HPC- 
MLV containing different PEG-lipids (PEGz000DSPE, 
PEG2000DPPE and PEGs000DPPE) by repeated extrusion 
through polycarbon membranes. Size and size distribution 
determined by dynamic light scattering measurement were 
compared with HPC-SUV. 
In order to obtain optimal results with regard to these 
properties of liposomal populations, the number of neces- 
sary extrusions was found to be between 15 and 19. A 
further increase of up to 49 passages resulted in a very 
narrow size distribution with PI of 0.012 + 0.028 (n = 6) 
and only a slightly reduced mean size of 118_ 23 nm 
(found for HPC-LUVETs with PEG2000DSPE). 
There was no significant difference between LUVETs 
(unpublished ata) and PEG-LUVETs, neither in size nor 
in size distribution (Table 1). Size of both vesicle types 
was only dependent on filter pore size (Fig. 1). The 
smallest distribution and therefore the most homogeneous 
vesicle population was obtained by 19-fold extrusion 
through filter with pores of 200 nm diameter (PI: 0.079) 
for HPC-liposomes without PEG-lipid (not shown) and 
through filter of 100 nm pore size (PI: 0.07) for liposomes 
with additional PEG-PE. 
Contrary to HPC-liposomes, PEG-HPC-vesicles were 
found to be stable even in the absence of DCP (Table 1). 
The small diameter (about 53 nm) of SUV with long chain 
length PEGso0oPE is remarkable compared to SUV made 
from the short derivatives or to nonpegylated SUV (be- 
tween 77 and 98 nm). 
It is possible to modify the content of PEG-lipid in the 
liposomal composition without any problem concerning 
preparation within 0 to 10 tool%. Size (not shown) was 
found to be between 120_+29 nm and 123_+28 (P! 
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Table l 
Influence of PEG-lipid, dicetyl phosphate and preparation method on vesicle-size and distribution 
APC Type of liposome PEG-PE DCP content Diameter (nm) PI ~ 
HPC SUV - + b 74 -+ 28 0.306 _+ 0.046 
LUVET - + 131 _+ 5 0.067 -+ 0.030 
HPC MLV PEG2oooDSPE + 858 + 204 0.887 _+ 0.060 
- ~ 800 _+ 206 0.880 -+ 0.062 
PEG2o0oDPPE + 330-+ 9 0.583 + 0.005 
533_+ 21 0.745 _+0.031 
PEGs0ooDPPE + 546 + 174 0.748 -+ 0.084 
- 604 _+ 109 0.769 _+ 0.056 
HPC SUV PEG20ooDSPE + 86 + 26 0.137 + 0.022 
- 84 _+ 26 0.160 _+ 0.022 
PEG2oooDPPE + 98 _+ 33 0.104 _+ 0.080 
PEGsoo0 DPPE + 53 +_ 17 0.200-+ 0.082 
- 54-+ 17 0.170_+0.082 
HPC LUVET PEG2oooDSPE + 125 + 29 0.061 _+ 0.027 
- 114 + 27 0.075 + 0.030 
PEG2oooDPPE + 134 -+ 41 0.104 _+ 0.080 
PEGsoooDPPE + 114 _+ 34 0.338 _+ 0.183 
TPC LUVET PEG2ooo DSPE + 106 _+ 31 0.141 _+ 0.048 
EPC PEG2oooDSPE + 130 -+ 36 0.091 _ 0.054 
Liposomes were prepared from 1 nM MLV-suspensions (APC/CH/DCP/PEG-lipid with (+)  or without ( - )  DCP) by sonication (12 × 4 rain, SUV) or 
by repeated extrusion (19 times) through polycarbon filter of 100 nm size (LUVETs). Liposomes were characterized by dynamic light scattering. 
Unimodal results given as mean diameter -+ S.D. (n = 6). 
h APC/CH/DCP/PEG-Iipid (1 : 1:0.2:0.1, molar ratio). 
c APC/CH/PEG-Iipid (l:l:0.1, molar ratio). 
0.054-0.075) for LUVETs made from DSPE2000PE of 2, 5 
and l0 mol%. Therefore we added the PEG-lipid in a 
molar ratio to HPC of 1:20 for standard preparations. 
Sterically stabilized liposomes were also prepared from 
homologeous alkylphosphocholines with a shorter (TPC) 
or with a longer chain (EPC) without any problem (Table 
1). 
1000 1 
800 0,8 
[ 
6OO O,6 
i 400 0,4 { 
200 0,2 
0 0 
MLV 1000 400 200 100 50 
Size of filter pores (nm) 
Fig. 1. Influence of filter pore size on vesicle diameter during preparation 
of PEG-HPC-LUVETs  (concn.  1 mM;  composi t ion:  
HPC/Chol/DCP/PEG2000DSPE in a molar ratio of 1:1:0.2:0.1) by 
repeated extrusion through polycarbonate filter of indicated size, using a 
LiposoFast system were investigated. Size and size distribution was 
determined by quasielastic light scattering, using a Coulter Counter 
Accucomp System. Data representing unimodal results for size, given in 
nm (open bars) and distribution of vesicle size (closed bars), given as 
PI-factor (varying from 1 (polydisperse) to 0 (monodisperse)). Data 
represent the means-/-_ S.D. of three different liposomal preparations. 
3.2. Stabi l i~ o f  l iposomes 
The stability of PEG-vesicles in buffer was investigated 
by the use of 6(5)-carboxyfluorescein as a hydrophilic 
marker. CF was encapsulated in SUV and the release of 
marker was determined over a period of 5 to 6 months. 
Data are given in Table 2. After this time only 6% of 
encapsulated marker was released from SUV, prepared 
under addition of DCP. Using liposomes without this 
charged lipid the release was further decreased to 3.65%. 
Physical stability in human plasma was determined 
Table 2 
Release of 6(5)-carboxyfluorescein from PEG-HPC-SUV in buffer 
Liposome preparation Time (Days) Release a (%) 
With DCP 14 2.13 + 0.65 
Absolute content of 6CF: 28 2.53 -+ 0.62 
74.88-+0.95 lxg/Ixmol 63 3.86-+0.71 
I61 5.93_+0.71 
Without DCP 7 0.97 _+ 0.43 
Absolute content of 6CF: 28 1.52 + 0.68 
78.92_+9.63 Ixg/txmol 70 2.19_+ 1.15 
154 3.65 _+ 1.99 
20 mM SUV (HPC/CH/DCP/PEG20ooDSPE, 1:1:0.2:0.1 molar ratio) 
with encapsulated CF were prepared by sonication (Branson sonifier, 
6 × 4 min/20°C) and stored at 4°C. The determination f CF by fluores- 
cence measurement was done at 490/520 rim. 
a Given are the means_+ S.D. of three separate determinations. 
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using calcein as marker according to Allen [27]. The 
fluorescence of this marker is independent of pH changes 
in the range of 6.0-8.5 and circumvent interactions of 
fluorophore with changing proton concentrations. The re- 
lease was followed at least for 24 h, as the highest plasma 
levels of liposomes were found in vivo between 12 and 24 
h in different studies [15,32]. 
Following the leakage of calcein from MLV or SUV 
during more than 4 weeks in undiluted plasma demon- 
strated that the release is a process consisting of three 
phases (Fig. 2). The first, initial phase was found to be a 
single exponential release turning into a second, the plateau 
phase. About 15-50% of the marker was released at this 
time from HPC-liposomes, whereas liposomes made from 
HePC released lower amounts (Table 3). The release was 
finished by a repeated enhancement after a longer time of 
plasma incubation (third phase). In the following experi- 
ments the plateau-time (PT) and the concentration of en- 
capsulated marker at this time were used for characteriza- 
tion of liposomal stability. 
We found two groups of liposomes. First group involv- 
ing MLV and LUVET (Table 3, preparations 3-8) showed 
low PT-values between 0.5 and 2 h. Up to half of the 
marker (22.4-58.7%) was released uring this time. The 
second group (preparation 9-12) consisted only of SUV of 
different preparations and was found to have PT-times 
greater 6 h. 
The amount of released marker was generally lower 
than in the first group. Especially SUV with DCP were 
very stable after an initial release of 16.1 resp. 23.7% of 
total marker. 
Control liposomes made from hydrated egg yolk lecithin 
in a similar composition were included in this study (Table 
3, preparation 1 and 2). These liposomes were also quite 
stable, but had very short PT accompanied with a low level 
of released marker. 
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Fig. 2. Release of calcein from different liposomal preparation was 
determined after incubation in human plasma (concentration 100 ~M) by 
fluorescence measurement a 490 nm excitation wavelength and 520 
emission wavelength. Measurements were accomplished every 5 minutes 
during first hours and finally once every day. Given are the mean 
fluorescence units of two measurements 
Table 3 
Stability of HPC-liposomes in human plasma 
No Liposome PT Released Tt/2 Max calcein 
preparation (in min) ~ calcein (d) b (mmol/mol) d 
(%) ~ 
1 HePC-MLV ~ 10 2.4 > 12 98.2 
2 PEG-HePC-MLV ~ 60 5.4 5.7 647.3 
3 MLV 30 58.7 = 2.5 144.4 
4 LUVET r 55 26.9 > 1 63.6 
5 PEG-LUVET f 60 22.4 > 1 86.3 
6 PEG-MLV 60.5 35.2 = 16.8 244.5 
7 PEG-LUVET 100 45.7 0.08 19. I 
8 LUVET 110 57.8 0.04 90.3 
9 SUV ~ 400 21.7 > 1.08 20.3 
10 PEG-SUV f 400 32.0 --- 1.08 38.5 
11 SUV 1470 23.7 > 30 114.2 
12 PEG-SUV 2980 16.1 > 30 76.8 
Liposomes (HPC/CH/DCP, molar ratio 10:10:2; PEG-vesicles with 
additional 5% DSPE2000PEG) with encapsulated catcein were incubated 
with human plasma to a final concentration of 100 txM. The release of 
calcein was determined by fluorescence measurements a  490 nm (excita- 
tion wavelength) and 520 nm (emission wavelength) after incubation of 
the liposomal suspensions in human plasma to a final concentration of
100 ~M. 
a Plateau time, time necessary to reach the plateau level of marker 
release. 
b Time for the release of 50% of encapsulated marker. 
" Amount of marker found in liposomes at plateau level (in percent of 
total encapsulated marker). 
d Amount of total marker found in liposomes after destruction by addition 
of Triton X. 
e Liposomal lipid used was HePC in place of HPC. 
f Preparations without DCP. 
3.3. In vitro results 
We investigated the macrophage activating properties of 
PEG-HPC-MLV compared to HPC-MLV with respect o 
stimulation of NO- and TNF-release. 
Whereas HPC-MLV caused a clear increase in NO-re- 
lease from 80 pg/ml  released from control macrophages 
to 158 pg/ml  after stimulation for 48 h in vitro, the 
liposomes with PEG-PE had no significant influence on 
NO neither after 4 nor after 48 h of coincubation (Fig. 3). 
The TNF content in the supernatant was determined in 
vitro as a second marker of macrophage activation. 
Macrophages cocultured in vitro with HPC-MLV or with 
the classical activator LPS were found to release up to 
10-fold (liposomes) or 30-fold (LPS) more TNF than the 
control macrophages (Fig. 4, left set of bars). PEG-HPC- 
MLV were again without any effect. The combination of a 
first in vivo application of liposomes, with a second activa- 
tion in vitro changed the situation (Fig. 4, bar set in the 
middle): the HPC-MLV induced release was decreased to 
the control level, whereas the LPS induced TNF amount 
was further increased. In contrast, the TNF release from 
macrophages stimulated in vivo with PEG-HPC-MLV (Fig. 
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40 
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without HPC-MLV PEG-MLV 
Fig. 3. Stimulation of NO release from mouse peritoneal macrophages 
was determined in in-vivo pre-treated (80 mM HPC-MLV or PEG-HPC- 
MLV) or untreated mouse peritoneal macrophages after isolation and 
culturing (1 • 105 in 200 Ixl RPMI 1640/well). The concentration of NO 
is given in pg/ml. All determinations were carried out in quadruplicate in 
at least three independent experiments. 
12 
10 
8 
0 
Carbon clearance from blood; t 1/2 (rain) 
1 2 4 24 72 
Hours after liposome administration 
Fig. 5. Carbon clearance from blood circulation in mice after pretreatment 
with different HPC-liposomes was determined for MPS uptake. Four 
mice/group were pretreated with HPC, liposomes or physiologic saline 
i.p. After different times (see diagram), india ink was administered i.v. 
and ink was determined spectroscopically at 650 nm in 25 Ixl blood 
samples, taken from the retroorbital venus plexus. The elimination half 
life (t l /2) in minutes was calculated. 
4, right set of bars) gave similar results as the release from 
macrophages without any pretreatment in vivo. 
3.4. In vico results 
The measurement of carbon clearance from blood is a 
suitable method to assay the function of the mononuclear 
phagocytic system. In accordance with our expectations 
the application of HPC-MLV resulted in a clear time 
dependent reduction in uptake of second vesicles like 
carbon particle from the blood circulation (Fig. 5). The 
strongest depression in phagocytic clearance of carbon 
(highest tl/2) was achieved with 'conventional' MLV after 
24 h from the administration. The free micellar HPC and 
the sterically stabilized HPC-liposomes were found to have 
TNF-Release Index 
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40 
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20 
10 
0 
without HPC-MLV PEG-MLV 
in vivo priming 
Fig. 4. Production of TNF from mouse peritoneal macrophages was 
determined on in vivo pretreated (80 mM HPC-MLV or PEG-HPC-MLV) 
or untreated mouse peritoneal macrophages after coculturing in vitro 
(1.105 in 200 txl RPMI 1640/well) with 100 mM HPC-MLV, 100 mM 
PEG-HPC-MLV or LPS (50 mg/ml)  for 4 h. TNF determination was 
done as described in Section 2. TNF-release is given as TNF release 
factor (TR). All determinations were carried out in quadruplicate in at 
least three independent experiments. * Levels of TNF were found to be 
beyond maximum determination limit; thus no S.D. value could be 
calculated. 
no influence on the MPS, as the tl/2 for elimination of 
carbon particles was similar to the control group. 
4. Discussion 
In previous studies [22-24] we have investigated the 
potency of HPC for macrophage activation to tumoricity. 
In the present investigation we were interested in the 
conditions to circumvent he MPS uptake of HPC-vesicles 
in order to improve the targeting of this cancerostatic 
compound to tumor site. 
The preparation of sterically stabilized liposomes by 
coating of vesicles with poly(ethylene glycol)-PE, the most 
common method, was carried out mostly with natural 
lipids. No experience with PEG-vesicles prepared from 
HPC has been reported so far. The aim of our study 
presented here was to investigate the preparation of PEG- 
HPC-liposomes of a defined size and the comparison of 
classical HPC-liposomes with PEG-liposomes with regard 
to their macrophage activating properties. 
Preparation of PEG-LUVETs by an extrusion technique 
[26,33,34] or of PEG-SUV by sonification from HPC-MLV 
was done without any problem. Whereas the sonification 
technique resulted in SUV of a more or less homogeneous 
and defined diameter, the size of extruded vesicles is 
related mainly to polycarbon filter size. This offers the 
opportunity to produce liposomes with a defined size open 
to selection. The vesicle size was related to the pore size, 
but not similar to it. Filter up to 200 nm pore size 
produced vesicles with a smaller diameter, pore size of 100 
and 50 nm resulted in vesicles with a diameter being 
clearly greater than the pore size. This was also found with 
liposomes made from phosphatidic acid, whereas other 
lipids (phosphocholine or phosphatidylserine) formed LU- 
VETs of diameters distributed below the pore size [26]. 
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Vesicle populations of LUVETs are more homogeneous 
with respect o size than SUV made by sonication or by 
French press technique [35]. Especially the use of filter 
pore sizes of 200, 100 and 50 nm produced liposome 
preparations with a very narrow size distribution, whereas 
the larger pore sizes gave broader ones. This effect could 
be explained by the inhomogeneous character of the MLV 
population, consisting not only of large vesicles, but also 
of smaller ones (data not shown), which are then not 
effected by the extrusion. 
In agreement with other data [17], most stable sterically 
stabilized HPC-LUVETS and SUV were prepared with a 
PEG content of 5-10 mol%. The PEG-lipid seems to 
stabilize the HPC-vesicle. Whereas HPC forms stable vesi- 
cles only in the presence of cholesterol and a negatively 
charged component like dicetyl phosphate [3] or 1,2-di- 
palmitoyl-sn-glycero-3-phosphoglycerol [35], PEG-HPC- 
SUV without a charged component were as stable as 
liposomes with DCP. We assume that the PEG-chains, 
surrounding the vesicle, protect hem against lipid related 
charges of other liposomes and reduce the liposome-lipo- 
some interactions. 
A prerequisite for therapeutical use is the stability of 
liposomes during storage and in biological fluids. To con- 
tinue on data from earlier studies [3] we characterized the 
storage stability of liposomes by measuring the CF leakage 
from vesicles in buffer (pH 7.4). Size determinations 
showed first that the release of marker was not accompa- 
nied with a shift in size or size distribution (data not 
shown). Taking into account hat the liposomal membrane 
itself consists of the physiological active lipid, a slow 
release of encapsulated dye should be a marker for mainte- 
nance of the vesicular structure and thus for intact lipo- 
somes. 
In biological systems HPC-liposomes hould be stable 
at least for 24 to 48 h, because peak plasma concentrations 
of the HPC [36] and of PEG-liposomes [15,16,32] made 
from other lipids were found in blood circulation during 
this time. 
Our data for stability obtained at 25°C using calcein as 
marker are in a good agreement with data resulting from 
HPC-SUV with encapsulated CF marker at 37°C in human 
serum [35]. The retention of marker was in both experi- 
ments characterized by a fast initial release followed by a 
longer stable phase at a level of about 30-50% of total 
amount of encapsulated marker without an additional re- 
lease. Concerning the T~/2 times we characterize the 
HPC-liposomes as stable, compared to data from other 
studies. Whereas the stability of liposomes made from 
saturated natural lipids [27] are in the range of up to 
several hours we determined T~/2 times up to days. 
This stability could be explained in part by the high 
amount of cholesterol necessary to prepare the HPC lipo- 
somes. The mixture of the single chain lipid HPC with 
cholesterol compensate he missing second aliphatic chain 
usually found in natural lipids and could further explain 
the observed high retention of encapsulated hydrophilic 
marker. Cholesterol is well known to enhance the rigidity 
of the tiposomal membrane [9,37,38]. A similar influence 
was also found with palmitoylphosphatidylethanolamine 
[39]. On the other hand this does not explain the variation 
in stability between the different liposomal preparations. 
Based on the similar liposomal composition the prepara- 
tion method should have an important influence on the 
molecular structure of the membrane, resulting in defects 
or gaps in the bilayer (MLV or LUVET) or in liposomes 
with a more regular bilayer (SUV). In some reports [40,41] 
SUV made from other lipids were of a similar stability 
characteristic or were even stabilized in serum by blood 
proteins [42]. 
Besides the high stability of all HPC-vesicles in buffer 
and in plasma, a superior effect by sterical stabilization 
was not observed. 
Because sterical stabilization should result in a reduced 
interaction between liposomes and MPS we extended this 
study to experiments of macrophage activation in vitro and 
in vivo. 
We found in first experiments in vitro that the direct 
cytotoxic effect of PEG-HPC-liposomes on tumor cells 
was similar to liposomes without PEG-PE (unpublished 
data). The next question was directed to the macrophage 
activating potency of PEG-liposomes. We found in previ- 
ous studies [22-24] that HPC-liposomes (without PEG) are 
able to induce a release of the well known mediators for 
cytotoxic activity - TNF and NO [43,44] - from 
macrophages. Remarkable is the synergistic effect of these 
liposomes with lipopolysaccharide, resulting in an en- 
hanced release of the mentioned markers [23,24]. 
It is known that the coating of vesicles with PEG-de- 
rivatives reduces the uptake by the MPS [16,17]. Thus a 
macrophage activation should be minimized if PEG-HPC- 
tiposomes are coincubated with the cells. Whereas in 
previous experiments he influence of liposomal composi- 
tion on macrophage activation compared to control lipo- 
somes made from hydrated egg phosphocholine was inves- 
tigated [23], we compared in this study directly the effect 
of sterically stabilized liposomes with plain liposomes 
(control iposomes) of similar composition and size. 
Activation of macrophages by PEG-vesicles was dimin- 
ished as expected compared to HPC-liposomes. This was 
found both in the coculture in vitro and in experiments 
with a combined activation in vivo/in vitro. These indi- 
cate that the interaction of HPC-liposomes with 
macrophages is reduced if vesicles are coated by incorpo- 
rating PEG-PE into the vesicular bilayer. First results in 
quantifying this direct effect in vitro by the measurement 
of phagocytic uptake of liposomal HPC confirm this obser- 
vation (data unpublished). 
Additionally, a reduced uptake of PEG-liposomes by 
the MPS could be demonstrated with the carbon ink uptake 
experiments in vivo. These data gave indirect evidence for 
the reduced interaction of PEG-HPC-liposomes with the 
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MPS and should thus lead to an improvement of antitumor 
activity by an increasing concentration of the drug at 
tumor site. Further experiments o confirm these results in 
vivo are under investigation. 
Our results with PEG-HPC-liposomes encourage the 
hope for a more efficient application form of liposomes 
made from HPC. A better targeting of HPC to tumor could 
finally result in an increased therapeutic index of HPC. 
Experiments are now ongoing to proof this conclusion by 
determining the organ distribution of free or liposomal 
HPC with or without sterically stabilization and to test 
these liposomes on different mammary carcinomas in nude 
mouse models. Additionally, these 'cytotoxic liposomes' 
should be an interesting application possibility used for the 
encapsulation of other antineoplastic drugs. The reduction 
in MPS uptake obtained by sterically stabilized liposomes 
opens the way to deliver a combination of two drugs with 
different modes of action more efficiently to tumor site 
with an additional or synergistic effects. 
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